In the largest study to date of the potential for drug drug interaction to reduce tamoxifen s protection against breast cancer recurrence, we examined whether Danish breast cancer patients with oestrogen receptor positive tumours who were treated with tamoxifen for 1, 2, or most often for 5 years had a higher rate of recurrence if they were concomitantly taking the SSRI citalopram or its S stereoisomer citalopram from here onwards than if they were not <a href=http://buycialis.homes>buy cialis online in usa</a>